Affordable Access

deepdyve-link deepdyve-link
Publisher Website

A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer.

Authors
Type
Published Article
Journal
Chemotherapy
1421-9794
Publisher
S. Karger AG
Publication Date
Volume
58
Issue
4
Pages
257–263
Identifiers
DOI: 10.1159/000341274
PMID: 22907396
Source
Medline
License
Unknown

Abstract

Irinotecan 60 mg/m2 on days 1 and 8 combined with carboplatin AUC 5 every 21 days is recommended for phase II evaluation. This regimen has clinical activity, acceptable toxicity and greater dose intensity over those currently tested in phase III trials.

Statistics

Seen <100 times